Literature DB >> 12704175

Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice.

L A Woodward1, H Arimitsu, R Hirst, K Oguma.   

Abstract

Two proteins representing the heavy-chain subunits of botulinum neurotoxin types C and D were expressed in Escherichia coli, and their vaccine potential was evaluated. Mice were vaccinated with doses ranging from 0.5 to 10 microg and were challenged with 10 to 10(5) 50% lethal doses of toxin. For the type C subunit protein, C50, two doses of 2 microg were required for full protection, while, for type D subunit protein, D50, two 1- microg doses were required. A bivalent vaccine consisting of a mixture of these two proteins also provided protection against both botulinum neurotoxin type C and type D challenge. Antibody levels in serum were determined by both enzyme-linked immunosorbent assays and serum neutralization assays

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704175      PMCID: PMC153265          DOI: 10.1128/IAI.71.5.2941-2944.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  11 in total

1.  Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin.

Authors:  J L Holley; M Elmore; M Mauchline; N Minton; R W Titball
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

2.  Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris.

Authors:  K J Potter; M A Bevins; E V Vassilieva; V R Chiruvolu; T Smith; L A Smith; M M Meagher
Journal:  Protein Expr Purif       Date:  1998-08       Impact factor: 1.650

3.  A common subunit structure in Clostridium botulinum type A, B and E toxins.

Authors:  B R DasGupta; H Sugiyama
Journal:  Biochem Biophys Res Commun       Date:  1972-07-11       Impact factor: 3.575

4.  Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli.

Authors:  N F Fairweather; V A Lyness; D J Maskell
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

5.  Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity.

Authors:  C C Shone; P Hambleton; J Melling
Journal:  Eur J Biochem       Date:  1985-08-15

Review 6.  Strategies for achieving high-level expression of genes in Escherichia coli.

Authors:  S C Makrides
Journal:  Microbiol Rev       Date:  1996-09

7.  The complete amino acid sequence of the Clostridium botulinum type D neurotoxin, deduced by nucleotide sequence analysis of the encoding phage d-16 phi genome.

Authors:  H Sunagawa; T Ohyama; T Watanabe; K Inoue
Journal:  J Vet Med Sci       Date:  1992-10       Impact factor: 1.267

8.  Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes.

Authors:  T Nishiki; Y Kamata; Y Nemoto; A Omori; T Ito; M Takahashi; S Kozaki
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

9.  Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.

Authors:  M A Clayton; J M Clayton; D R Brown; J L Middlebrook
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

10.  Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves.

Authors:  J D Black; J O Dolly
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

View more
  9 in total

1.  Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons.

Authors:  Abby R Kroken; Andrew P-A Karalewitz; Zhuji Fu; Jung-Ja P Kim; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

2.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

3.  Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.

Authors:  R Zichel; A Mimran; A Keren; A Barnea; I Steinberger-Levy; D Marcus; A Turgeman; S Reuveny
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

4.  High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E.

Authors:  Ebrahim Valipour; Mir-Latif Moosavi; Jafar Amani; Shahram Nazarian
Journal:  World J Microbiol Biotechnol       Date:  2014-01-29       Impact factor: 3.312

5.  Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins.

Authors:  Hideyuki Arimitsu; Jae-Chul Lee; Yoshihiko Sakaguchi; Yuji Hayakawa; Michiko Hayashi; Miki Nakaura; Hikaru Takai; Song-Nan Lin; Masafumi Mukamoto; Tom Murphy; Keiji Oguma
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

6.  Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.

Authors:  Yun-Zhou Yu; Na Li; Rui-Lin Wang; Heng-Qi Zhu; Shuang Wang; Wei-Yuan Yu; Zhi-Wei Sun
Journal:  Clin Vaccine Immunol       Date:  2008-10-08

7.  Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.

Authors:  M Zouhair Atassi; Behzod Z Dolimbek
Journal:  Protein J       Date:  2004-01       Impact factor: 4.000

8.  Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Authors:  Luciana A F Gil; Carlos Eduardo P da Cunha; Gustavo M S G Moreira; Felipe M Salvarani; Ronnie A Assis; Francisco Carlos F Lobato; Marcelo Mendonça; Odir A Dellagostin; Fabricio R Conceição
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

9.  An adenoviral vector-based mucosal vaccine is effective in protection against botulism.

Authors:  Q Xu; M E Pichichero; L L Simpson; Md Elias; L A Smith; M Zeng
Journal:  Gene Ther       Date:  2009-01-08       Impact factor: 5.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.